Aviva’s Pacific Biosciences PACB Stock Holding History

Aviva’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-735,222	Closed	-$2.25M	–	960
2020 Q1	$2.25M	Buy	735,222 +372,159	+103%	+$1.52M	0.02%	706
2019 Q4	$1.87M	Buy	+363,063	New	+$1.85M	0.01%	797

Other funds holding PACB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KLCMU

Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Aviva's PACB Position: Q2 2020 in Review

Aviva sold out of Pacific Biosciences (PACB) in Q2 2020, closing a stake of 735,222 shares — an estimated $2.25M sold.

Aviva first reported a position in PACB in Q4 2019 and held it in 2 quarters. The position peaked at $2.25M in Q1 2020. 151 funds tracked by Wall St. Rank hold PACB as of Q2 2020.

Aviva reported no remaining Pacific Biosciences position as of Q2 2020 after selling out during the quarter.
Aviva sold 735,222 Pacific Biosciences shares in Q2 2020, an estimated $2.25M.
Aviva first reported a position in Pacific Biosciences in Q4 2019 and held it in 2 quarters.
Aviva's Pacific Biosciences position peaked at $2.25M in Q1 2020.
151 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2020.

Based on Aviva's 13F filing for Q2 2020, filed 13 Aug 2020.